Mostrar el registro sencillo del ítem

dc.contributor.authorGarcía-Benítez, María Regla
dc.contributor.authorReal, María Montserrat
dc.contributor.authorFernández, Paloma
dc.contributor.authorBermejo-Sanchez, Eva 
dc.contributor.authorMartínez-Frías, María Luisa 
dc.date.accessioned2022-04-18T11:54:23Z
dc.date.available2022-04-18T11:54:23Z
dc.date.issued2011-12
dc.identifier.citationBoletín del ECEMC: Rev Dismor Epidemiol 2011; VI (nº 1): 134-147es_ES
dc.identifier.issn0210–3893es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/14082
dc.descriptionTeratología Clínicaes_ES
dc.description.abstractThe objective of this study was to epidemiologically analyze urinary tract infections (UTI) suffered by pregnant women, and the prenatal exposure to Fosfomycin. To accomplish this objective, data from the Spanish Collaborative Study of Congenital Malformations (ECEMC) were analyzed for the period 1978-2009. A total of 40,060 newborn infants with congenital defects, and a similar number of healthy controls were registered. The proportions of mothers of cases and controls who suffered UTI during the first trimester were 2.69% and 2.56%, respectively. These figures go up to 9.94% and 8.86% when considering UTI at any time during pregnancy. The proportions of mothers who were treated with fosfomycin during the first trimester of pregnancy were 0.67% and 0.69%, respectively for cases and controls, and those figures go up to 2.69% y 2.54% when considering exposures at any time during pregnancy. Use of fosfomycin at any time during pregnancy has progressively increased with time. When studying the geographical distribution of the frequency some differences regarding UTI and use of fosfomycin were detected. The increase in use of fosfomycin has caused a decrease of the use of other antibiotics, and these trends are also observed in several autonomous regions in Spain. The use of fosfomycin during pregnancy seems to be safe, and suffering an UTI is quite common during pregnancy and somehow dangerous for the progress of gestation. It is important to underline that the percentage of mothers without treatment was between 20 and 35%. Therefore, it is advisable to treat UTI as soon as possible, in order to avoid complications both for the mother and fetus.es_ES
dc.language.isospaes_ES
dc.publisherInstituto de Salud Carlos III (ISCIII). Instituto de Investigación de Enfermedades Raras (IIER) es_ES
dc.type.hasVersionVoRes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectInfección urinariaes_ES
dc.subjectFosfomicinaes_ES
dc.subjectEmbarazoes_ES
dc.subjectEpidemiologíaes_ES
dc.subjectUrinary tract infectiones_ES
dc.subjectFosfomycines_ES
dc.subjectPregnancyes_ES
dc.subjectEpidemiologyes_ES
dc.titleAnálisis Epidemiológico de las infecciones urinarias y la exposición a Fosfomicina durante el embarazo en madres de niños con y sin defectos congénitos: Distribución por años y por comunidades autónomases_ES
dc.title.alternativeEpidemiological analysis of urinary tract infections and exposure to Fosfomycin during pregnancy in mothers of infants with and without congenital defects: Distribution by years and Autonomous Regionses_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.format.volumeVIes_ES
dc.format.number1es_ES
dc.format.page134-147es_ES
dc.description.peerreviewedNoes_ES
dc.identifier.journalBoletín del ECEMC: Revista de Dismorfología y Epidemiologíaes_ES
dc.repisalud.centroISCIIIes_ES
dc.repisalud.institucionISCIIIes_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail
Acceso Abierto

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional